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Background: Increased oxidative stress or an impaired antioxidant defense mechanism may play a crucial role in
the onset and progression of atherosclerosis. Recently, Paraoxonase −1 (PON1) which accounts for most of the
antioxidant effect of high density lipoprotein (HDL) cholesterol has been presented as a potential therapeutic agent
against atherosclerosis development. Allele frequencies for PON1 gene that influence enzyme concentration as well
as activity differ greatly among ethnic groups and data from several studies showed ethnic variations in the interpretation
of cardiovascular disease (CVD) associated with PON1 polymorphisms. In this work, we investigated PON1 Q192R
and L55M polymorphisms in Egyptian patients with type 2 diabetes mellitus (T2DM) and its association with CVD.
Methods: The study included 184 subjects classified into 3 groups; T2DM, T2DM+ CVD, and healthy controls. PON1
polymorphisms were genotyped by real-time PCR and PON1 concentration was assayed in serum by ELISA
(enzyme linked immunesorbent assay).
Results: Genotype and allele frequencies of Q192R were significantly different between controls and diabetic
patients. Frequency of QQ genotype was significantly higher in healthy controls, while QR and RR genotypes
were significantly higher in diabetic patients (p = 0.02). Frequency of 55LL and LM genotypes were significantly
higher in patients than in controls (p = 0.009). Q192R polymorphism associated with CVD in our diabetic patients
(p = 0.01) and with low serum PON1 concentration (p = 0.04). Multiple logistic regression analysis revealed significant
correlations between 192R and other independent CVD risk factors.
Conclusion: PON1 192R and 55 L alleles are associated with T2DM. Q192R polymorphism is associated with CVD and
lower serum enzyme concentration and might represents a novel risk factor for CVD in Egyptian patients with T2DM.
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Diabetes mellitus (DM) is a chronic life-threatening dis-
ease and is the second leading cause of death worldwide
with at least 1 in 10 deaths among adults between 35 and
64 years old is attributable to diabetes [1]. Cardiovascular
disease (CVD) is the most common cause of morbidity
and mortality among diabetic patients. People with dia-
betes are 2 to 4 times more likely to develop coronary
artery disease (CAD), 5 times more likely to develop
peripheral vascular disease (PVD), and 2 to 6 times more
likely to develop myocardial infarction (MI) or stroke than* Correspondence: d_lebedy@yahoo.co.uk
Department of Clinical and Chemical Pathology, Medical Research Division,
National Research Center, Al-Bohouth Street, Cairo 12311, Egypt
? 2014 El-Lebedy et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.people without diabetes [2]. Several factors such as dys-
lipidemia, obesity, smoking, exercise, alcohol intake,
oxidative stress and genetic variants have been identified
as risk factors for CVD in type 2 diabetes (T2DM) [3].
Recently, ? dysfunctional HDL? or ? proinflammatory HDL?
was indicated as a proatherogenic factor [4]. The protective
function of HDL against atherogenesis could be partly
explained by its main constituent, PON1 (paraoxonase-1)
[5]. PON1 is a 355 amino acid glycoprotein which is syn-
thesized in the liver and secreted into the blood where it
associates with HDL and accounts for most of its antioxi-
dant effect to prevent oxidation of LDL [6,7].
Increased oxidative stress or an impaired antioxidant
defense mechanism may play a crucial role in the onsetl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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concentration and/or activity might have a deleterious ef-
fect on the protective function of HDL [9]. PON1 has been
the focus of intensive research and has been reported as an
independent risk factor for CVD [10]. The most convincing
data to link PON1 with heart disease comes from trans-
genic mouse studies. HDL from PON1 ? knockout ? mice
have an increased capacity to oxidize LDL and are more
prone to develop atherosclerosis than their wild-type sib-
lings as a consequence of increased oxidative stress [11].
Two single nucleotide polymorphisms in the PON1
coding region affect the anti-atherogenic properties and
have been associated with risk for CVD [12], a substitution
of glutamine (Q) for arginine (R) at position 192 (Q192R)
and a substitution of leucine (L) for methionine (M) at
position 55 (L55M) [13-16]. The Q192R polymorphism
alters the enzyme? s ability to protect LDL from oxidation
in vitro with 192Q is the most protective, while L55M
polymorphism affects the enzyme concentration with
55 M is associated with lower serum concentration [17].
Data from several studies showed ethnic variations in
the interpretation of CVD associated with PON1 poly-
morphisms [18-21]. The aim of this work is to investigate
PON1 Q192R and L55M polymorphisms in Egyptian pa-




The studied subjects were recruited from the Outpatients?
Clinic of the National Research Center and National Dia-
betes & Endocrinology Institute, Cairo, Egypt. Data of
family and medical history, smoking habits and physical
activity was obtained by questionnaire. Cigarette smokers
were considered if they had once smoked even if they were
no longer smokers, and physical activity was defined as ex-
ercise for 2? 3 days/week for at least 30 minutes. Clinical
examination including systolic blood pressure (SBP) and
diastolic blood pressure (DBP) measurements was applied.
Anthropometric measurements (weight and height) were
collected and used for BMI calculation according to the
standard formula BMI =weight (kg)/[height (m)]2. Hyper-
tension was defined as blood pressure above 140/90 mmHg
or taking antihypertensive drugs. According to the criteria
of American Diabetes Association Classification 2010 [22],
subjects were classified into 3 groups:
Normal healthy control group
Included 50 subjects with fasting plasma glucose (FPG) <
100 mg/dL. Exclusion criteria were hyperlipidemia,
hypertension, family history of any form of CVD, dia-
betes mellitus, hepatic and renal diseases, endocrine
disease, metabolic disorders, autoimmune diseases and
those under medication.T2DM patients without CVD
Included 68 subjects fulfilled the diabetes mellitus diag-
nostic criteria of FPG ≥ 126 mg/dL or were under antidi-
abetic treatment (oral and/or insulin) with no history or
signs of any CVD. Exclusion criteria included renal dis-
ease, hepatic disease, endocrine disease, other metabolic
disorders and autoimmune diseases.
T2DM complicated with CVD
Included 66 subjects diagnosed to have diabetes with FPG ≥
126 mg/dL or under antidiabetic treatment and compli-
cated with any of the vascular disease e.g. ischemic heart
disease (IHD), macroangiopathy and/or cerebrovascular
disease. Exclusion criteria included renal disease, hepatic
disease, endocrine disease, other metabolic disorders and
autoimmune diseases.
Informed consent was obtained from all subjects and
the study protocol was approved by the Ethics Commit-
tee of the National Research Center.
Methods
Lipid analysis and biochemical markers
Venous blood samples were collected from all subjects
after 12 hours of overnight fast. Total cholesterol (TC),
Triglycerides (TG), high density lipoprotein (HDL-C),
glucose and glycosylated hemoglobin (HbA1c) were quan-
tified using an automated clinical chemistry analyzer Roche
Diagnostics (Germany). Low density lipoprotein (LDL-C)
level was calculated using Friedewald formula [23].
Genotyping of PON1 Q192R and L55M polymorphisms
Genomic DNA was isolated from whole peripheral blood
using QIAamp DNA extraction kit (Qiagen Hilden,
Germany, Cat no. 51304) according to the manufacturer ? s
protocol.
L55M (rs854560) and Q192R (rs662) polymorphisms
of the PON1 gene were determined by Taqman-based
allelic discrimination assay using the following primers
and probes: For L55M: 5′-TTTCTGTTCTCTTTTCTG
GCAGAAA-3′ forward and 5′-GAAAACACTCACAG
AGCTAATGAAAGC-3′ reverse; 55 M: 5′-FAM-CCAT
TAGGCAGTATCTCCATGTCTTCAGAGCC-3′ and 55 L:
5′- VIC-TCCATTAGGCAGTATCTCCAAGTCTTCAG
AGCC-3′. For Q192R: 5′-GGACCTGAGCACTTTTA
TGGCA-3′ forward and 5′-GACAACATACGACCAC
GCTAAACC-3′ reverse; 192Q: 5′-FAM-TTCTTGACC
CCTACTTACAATCCTGGGAGATGT-3′ and 192R: 5′-
VIC-CTTGACCCCTACTTACGATCCTGGGAGATGT-3′.
All primers and probes were designed by Applied Bio-
systems. Genotyping assays were performed on ABI 7500
Real Time PCR (Applied Biosystems). The genotyping
success rates were greater than 95% for all SNPs. For the
genotyping quality control, 10% of samples were randomly
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rate was 100%.
Assay of PON1 enzyme concentration in serum
Serum PON1 concentration was measured by enzyme
linked immunosorbent assay (ELISA) using Human
Paraoxonase-1 (PON1) ELISA kit Cat# 95462 (Glory
Science Co., Ltd, TX, USA).
Statistical analysis
Data were analyzed using SPSS version 16.0 for Windows
(Chicago, IL, USA). Chi-square was used to test the differ-
ence in genotypes frequency between the groups. Means
of serum PON1 concentration according to different
genotypes were compared using analysis of variance
(ANOVA) and t-tests. Logistic regression analysis and
odds ratios were calculated to test the association of geno-
types and CVD, keeping wild type as the reference. The
association of Q192R polymorphism with other CVD risk
factors was tested by multiple logistic regression analysis,
assessing independence from potential confounders. Vari-
ables such as age, male gender, smoking, BMI, SBP, TC,
HDL, LDL and TG were included into the logistic model.
P value less than 0.05 was considered significant.
Results
Our study included 184 subjects classified into 68 patients
with T2DM, 66 patients with T2DM+CVD, and 50 controlTable 1 General characteristics and biochemical variables of t
Variable Controls (n=50)
Age (Years) 51.24 ? 7.62
Sex (male/female) 27/23
BMI (kg/m2) 23.21 ? 4.62
SBP (mmHg) 121.90 ? 15.29
DBP (mmHg) 81.19 ? 8.93
Hypertension (%) -
Smokers (%) 9.5
Physical activity (%) 57.1
Diabetes duration (Years) -
Glucose (mg/dL) 84.90 ? 9.61
HbA1c (%) 5.42 ? 0.61
Triglyceride (mg/dL) 117.57 ? 31.28
TC (mg/dL) 186.86 ? 28.68
LDL-C (mg/dL) 111.95 ? 15.95
HDL-C (mg/dL) 55.71 ? 11.24
Serum PON1 (nmol/L) 18.87 ? 17.04
Significance was confirmed by Bonferroni test.
*Significant p in comparison between controls and T2DM, **Significant p in compa
T2DM and T2DM+CVD.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; H
cholesterol; HDL-C: high density lipoprotein cholesterol; VLDL-C: very low density lipsubjects. Our CVD patients were as follows: 45 (68%) had
ischemic heart disease (IHD), 7 (11%) had cerebrovascular
disease, 8 (12%) had macroangiopathy, 4 (6%) had com-
bined IHD and cerebrovascular, and 2 (3%) had combined
macroangiopathy and cerebrovascular disease.
The general characteristics and biochemical variables of
the study population
Demographic, clinical and biochemical data of different
groups is shown in Table 1. A significant age difference
was found between controls and CVD group (p < 0.01).
Also a significant sex difference was found between con-
trols and CVD group (p = 0.01) due to the high prevalence
of males among our CVD patients. Diabetic patients had
lower levels of physical activity (p = 0.01) as compared to
controls and patients with CVD had lower levels of phys-
ical activity when compared to patients without CVD (p =
0.005). There was a significant association between CVD
and the duration of diabetes (p = 0.004). Other clinical
data such as BMI, SBP and DBP were significantly higher
in both groups when compared to controls. CVD patients
had higher frequency of hypertension (p = 0.01) as com-
pared with patients without CVD.
The mean of serum PON1 enzyme concentration was
significantly lower in patient groups compared to controls
(p = 0.006). No significant difference was found between
diabetic patients with CVD and those without CVD
(p>0.05).he study population
T2DM (n=68) T2DM+CVD (n=66)
51.75 ? 6.00 58.20 ? 7.12**
38/30 50/16**
27.59 ? 4.90* 29.81 ? 5.55**
131.67 ? 20.60* 144.14 ? 21.16** ?




8.50 ? 7.41 13.00 ? 6.97 ?
146.83 ? 58.31* 164.00 ? 68.27**
6.30 ? 1.19* 6.61 ? 1.37**
143.61 ? 73.14* 169.00 ? 66.43** ?
193.92 ? 50.59* 206.71 ? 44.98** ?
129.22 ? 42.05* 141.60 ? 45.04** ?
49.93 ? 11.26* 41.97 ? 12.79** ?
7.82 ? 5.44* 9.22 ? 14.94**
rison between controls and T2DM+CVD, ? Significant p in comparison between
bA1c: hemoglobin A1c; TC: total cholesterol; LDL-C: low density lipoprotein
oprotein cholesterol; PON1: paraoxonase-1.
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patients vs. controls
Analysis of genotypes and alleles distribution of Q192R
and L55M polymorphisms in T2DM, with and without
CVD, and control subjects is shown in Table 2. Data re-
vealed that the genotype and allele frequencies of Q192R
were significantly different between controls and diabetic
patients. Genotype 192QQ was detected in 66% of con-
trols vs. 44.8% of diabetic patients, while QR and RR ge-
notypes were more frequent in diabetic patients than in
controls (44% and 11.2% vs. 24% and 10%, respectively),
p = 0.02. Allele Q was found in 78% of controls vs. 66.8%
of patients, while allele R was more frequent in patients
(33.2%) than in controls (22%); p = 0.03.
As regards L55M, the frequency of genotype MM was
higher in controls (58%) than in patients (33.5%), while
the frequency of genotypes LM and LL were higher in
patients than in controls (49.3% and 17.2% vs. 28% and
14%, respectively); p = 0.009. Allele M was found in 72% of
controls vs. 58% of patients, while Allele L was more fre-
quent in patients than in controls (42% vs. 28%); p = 0.015.
PON1 polymorphisms genotype and allele distribution in
T2DM patients with and without CVD
Analysis of genotypes and alleles distribution of Q192R
and L55M polymorphisms in T2DM and T2DM+CVD
patients is shown in Table 3. Results showed a significant
difference between the two groups with QQ genotype
more frequent in T2DM patients than in T2DM + CVD
patients (57.4% vs. 32%), while the frequency of QR and
RR genotypes were significantly increased in T2DM +
CVD (54.4% and 13.6% vs. 33.8% and 8.8%, respectively),
p = 0.01. Allele Q was detected in 74% of patients without
CVD vs. 59% of patients with CVD, while allele R wasTable 2 Genotypes and alleles frequency of PON1 Q192R
and L55M polymorphisms in patients and control groups
Control N=50 Patients N=134 OR (95% CI) P value
Q192R
QQ 33 (66%) 60 (44.8%) Reference 0.02
QR 12 (24%) 59 (44%) 2.1 (1.2? 4.8)
RR 5 (10%) 15 (11.2%) 3.2 (1.3? 6.6)
L55M
LL 7 (14%) 23 (17.2%) Reference 0.009
LM 14 (28%) 66 (49.3%) 2.1 (1.4? 5.5)
MM 29 (58%) 45 (33.5%) 2.8 (1.7-6.2)
Allele 2n=100 2n=268
192Q 78 (78%) 179 (66.8%) Reference 0.03
192R 22 (22%) 89 (33.2%) 1.9 (1.2? 3.2)
55 L 28 (28%) 112 (42%) Reference 0.01
55 M 72 (72%) 156 (58%) 2.0 (1.1? 3.5)more frequent in patients with CVD (41%) than in pa-
tients without CVD (26%); p = 0.008. No statistical sig-
nificant difference was found between the two groups
as regards L55M genotype distribution (p = 0.9) or alleles
frequency (p = 0.8).Effects of Q192R and L55M polymorphisms on PON1
serum enzyme concentration
Means of serum PON1 concentration according to differ-
ent genotypes are shown in Table 4. Q192R polymorphism
associated with low serum PON1 concentrations, and low-
est concentrations were observed in QR and RR genotypes
(p = 0.04). L55M did not associate with significant differ-
ence in enzyme concentration. Though patients with 55 L
allele had higher enzyme concentrations, yet that was of
no statistical significance (p = 0.18).Association of Q192R with CVD in T2DM patients
Multiple logistic regression analysis was used to investigate
potential correlations of 192R allele with other cardiovas-
cular risk factors: age, male gender, smoking, BMI, SBP,
TC, HDL, LDL and TG. We demonstrated statistical sig-
nificant correlations between 192R and age (ORs 1.39, 95%
CI 1.1? 1.73, p = 0.04), male gender (ORs 0.94, 95% CI
0.45 ? 0.86, p = 0.016), SBP (ORs 1.92, 95% CI 1.38 ? 2.78,
p = 0.007), TC (ORs 0.97, 95% CI 0.36 ? 0.86, p = 0.016),
HDL (ORs 2.21, 95% CI 1.38 ? 2.79, p = 0.001) and LDL
(ORs 3.20, 95% CI 2.31 ? 6.58, p = 0.001) and TG (ORs
0.54, 95% CI 0.36? 0.86, p = 0.012). No significant cor-
relations were detected with smoking (ORs 0.34, 95% CI
0.29? 0.79, p = 0.23) or BMI (ORs 0.54, 95% CI 0.24? 0.63,
p = 0.12).Table 3 Genotypes and alleles frequency of PON1 Q192R
and L55M polymorphisms in T2DM and T2DM+CVD
patient groups
T2DM N = 68 T2DM+CVD N=66 OR (95% CI) P value
Q192R
QQ 39 (57.4%) 21 (32%) Reference 0.01
QR 23 (33.8%) 36 (54.4%) 1.7 (1.0? 3.8)
RR 6 (8.8%) 9 (13.6%) 2.1 (1.3? 4.6)
L55M
LL 11 (35%) 12 (41%) Reference 0.9
LM 34 (47%) 32 (45 %) 1.08 (0.8? 1.4)
MM 23 (18%) 22 (14%) 0.99 (0.7? 1.2)
Allele 2n=136 2n=132
192Q 101 (74%) 78 (59%) Reference 0.008
192R 35 (26%) 54 (41%) 1.3 (1.0? 2.7)
55 L 56 (59%) 56 (64%) Reference 0.8
55 M 80 (41%) 76 (36%) 0.9 (0.8? 1.1)
Table 4 Means of serum PON1 concentration in different
genotypes of Q192R and L55M polymorphisms
Serum PON-1 mean?SD (nmol/L) P value
192 QQ 12.97 ? 15.75 0.04
192QR+192RR 8.95 ? 10.2
55MM 9.07 ? 6.22 0.18
55LM+LL 11.80 ? 15.77
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Oxidative modification of LDL is believed to be a major
triggering event in the initiation and progression of athero-
sclerosis and cardiovascular events [24]. Recently, PON1
became the focus of intense research after the identifica-
tion of its antioxidant properties, particularly its capacity to
protect LDL from oxidative damage.
In the present study, we investigated the association of
PON1 Q192R and L55M polymorphisms with the CVD in
T2DM in Egyptian patients. We found an association of
192R and 55 L alleles with T2DM. Serum PON1 enzyme
concentration was significantly reduced in our diabetic pa-
tients compared to controls and lowest enzyme concentra-
tions were associated with the 192R allele. As regards the
CVD, a significant association with 192R allele was dem-
onstrated. Serum concentration of PON1 was not signifi-
cantly different between diabetic patients with CVD and
those without CVD. Allele 55 L was previously reported
to be associated with higher concentrations of the enzyme
[25], but lower enzyme activity [18]. L55 isoform was
found to be more stable and resistant to proteolysis [26].
This could explain the relatively higher serum enzyme
levels found in our L allele carrier patients.
Our findings support the previously reported hypoth-
esis that reduced PON1 concentration and/or activity
might play a role in the pathogenesis of T2DM itself. It is
suggested that oxidative stress induced by reduced PON1
concentration and/or activity results in reducing glucose
uptake from blood by muscle cells and develops into insu-
lin resistance. Results from previous studies in which de-
creased PON1 activity and concentration has been linked
with impaired glucose tolerance [27,28] and increased in-
sulin resistance in healthy subjects [29,30] also support
this hypothesis. Reduced PON1 concentration and activity
in Type I and Type II diabetic patients has been reported
in many studies [31-36].
Logistic regression analysis with other independent risk
factors revealed an independent correlation of 192R with
CVD risk. The Q192R polymorphism in the PON1 gene
hampers the ability of PON1 to inhibit LDL oxidation,
suggesting that the 192R allele is less effective than 192Q
in preventing LDL oxidation [37,38]. Thus, carriers of the
R allele are more susceptible to develop CVD than carriers
of the Q allele. Randa et al. [39] reported that individuals
with PON1 RR genotype have 9-fold risks to developCAD in Egyptians while those with the PON1 QR geno-
type have 4-fold risks. Also, the risk factors for CAD
(diabetes, hypertension, dyslipidemia) were significantly
associated with PON1 RR genotype.
Lower PON1 activity was associated with carotid arterio-
sclerosis and cerebral atherosclerosis in stroke patients
[13], and was reported as a risk factor for CVD in sys-
temic lupus patients [14] and CAD in type 2 diabetes
in North-West Indians [15]. Also, an association be-
tween PON1 polymorphisms and CAD risk was dem-
onstrated in Thai population, where the frequencies of
192R allele and 192RR genotype, as well as, 55 M allele
and 55LM genotype were significantly higher in CAD
patients [16].
In a study by Ito et al. [40] involving the PON1-192R
allele and the environmental risk factors, PON1-192R al-
lele was reported as the most predictive independent risk
factor for coronary spasm followed by cigarette smoking.
Also, plasma levels of TBARS (Thiobarbituric acid-reactive
substances), markers of oxidative stress, were higher in RR
than in QQ genotypes suggesting that PON1-192R allele
may play an important role in the genesis of coronary
spasm, probably by attenuating the suppression of oxi-
dative stress.
In a recent study; including PON1 genotyping, activity
and lipid profile and their association with significant
coronary stenosis (SCS) in Tunisian population, PON1
activity was lower in patients with SCS than in controls.
Low activity was associated with 192R and 55 L alleles.
In the presence of diabetes, PON1-192RR genotype asso-
ciated with an increased risk of SCS while 55MM geno-
type associated with lower risk [18]. In contrast, in a study
on 589 patients (419 Caucasian, 120 South Asian, 50
other) to determine factors which modulate serum PON1
in type 2 diabetes, PON1 activity associated negatively
with insulin resistance, triglycerides and 55 M allele;
and positively with 192R allele. While PON1 concentra-
tion associated negatively with Caucasian ethnicity and
duration of diabetes, and positively with 192R allele [19].
Altuner et al. declared that RR genotype associated
with higher PON activity than QQ or QR genotypes,
while LL genotype associated with higher PON activity
than MM genotype in Turkish population [20]. In Asian
Indians, CAD was associated PON1 192R allele. Haplotype
LQ (55 L and 192Q) showed protective effect, while haplo-
type MR (55 M and 192R) was associated with increased
risk of CAD [21]. A recent meta-analysis of 88 studies
comprising 24,702 CAD cases and 38, 232 controls re-
vealed a significant association of Q192R polymorph-
ism with the disease risk [41]. The controversial data
in the interpretation of CVD association with PON1
polymorphism might be attributed to ethnic variation,
sample size, patients? recruiting criteria, gene? gene and
gene? environment interactions [42-45].
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Our results indicate that PON1 192R and 55 L alleles are
associated with T2DM, and suggest that they may play a
role in the pathogenesis of the disease. Q192R is associ-
ated with CVD and lower serum enzyme concentration
and might represent a novel risk factor for CVD in Egyp-
tian patients with T2DM.
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